Form 4: Gilead Sciences SVP, Controllership, Sandra Patterson, Reports Acquisition of Common Stock

Sandra Patterson, SVP, Controllership at Gilead Sciences, reports the acquisition of 709 shares of common stock due to performance share award vesting.

Summary

• Sandra Patterson, SVP, Controllership at Gilead Sciences, filed a Form 4 on February 6, 2025, reporting a transaction on February 4, 2025.
• She acquired 709 shares of Gilead Sciences common stock at $0 per share.
• This acquisition increased her direct holdings to 37,787 shares.
• The acquisition is related to performance share awards granted on March 10, 2024, which were subject to performance and service-vesting requirements.
• The performance vesting requirement was met on February 4, 2025, upon certification by the Compensation and Talent Committee, but the shares will be issued upon meeting service requirements.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects the achievement of performance goals and standard executive compensation practices.

Positives

• The vesting of performance share awards indicates that performance goals set by Gilead Sciences were achieved.

Future Outlook

The shares will be issued to the Reporting person once the requisite continuing service requirements are met.

Industry Context

Form 4 filings are routine disclosures for company insiders and provide transparency into their transactions in the company's stock.

Stakeholder Impact

• The vesting of performance shares aligns executive compensation with company performance, potentially benefiting shareholders.

Next Steps

• The shares will be issued to Sandra Patterson upon meeting the remaining service requirements.

Key Dates